Clinical Trials Browser

Interventional × Cholangiocarcinoma × Plasma cell × Clear all

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT06910670 2025-07-20

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

Phase NA Recruiting

240 enrolled

GastrointestinalPlasma cell

Multiple Myeloma, Colorectal Neoplasms, Cholangiocarcinoma

NCT06340646 2025-07-11

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Phase NA Recruiting

990 enrolled

GastrointestinalPlasma cell

Colonic Neoplasms, Multiple Myeloma, Rectal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

40 enrolled

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Clinical Trials

ETCABIO

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours